Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: The CAPELAL study

Haematologica

Volumn 93, Issue 10, 2008, Pages 1488-1494

  Hunault Berger, Mathilde ^a   Chevallier, Patrice ^b   Delain, Martine ^c   Bulabois, Claude Eric ^d   Bologna, Serge ^e   Bernard, Marc ^f   Lafon, Ingrid ^g   Cornillon, Jérome ^h   Maakaroun, Abdallah ^c   Tizon, Alexandra ^a   Padrazzi, Bruno ⁱ   Ifrah, Norbert ^a   Gruel, Yves ^c,j  

^a Hematology Department of Angers   (France)

^b Departments of Hematology   (France)

^c Hematology Department of Tours   (France)

^d Hematology Department of Grenoble   (France)

^e Immunology Department of Nancy   (France)

^f Hematology Department of Rennes   (France)

^g Hematology Department of Dijon   (France)

^h Hematology Department of Saint Etienne   (France)

ⁱ LFB Paris   (France)

^j SERVICE DE DERMATOLOGIE   (France)

more..

Author keywords

Acute lymphoblastic leukemia; Antithrombin; Fibrinogen; L asparaginase

Indexed keywords

ACLOTINE; ANTITHROMBIN; ASPARAGINASE; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; IDARUBICIN; LOW MOLECULAR WEIGHT HEPARIN; STEROID; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEMATOMA; HUMAN; LOW DRUG DOSE; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROPHYLAXIS; RECTUM HEMORRHAGE; STROKE; THROMBOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTITHROMBINS; ASPARAGINASE; FEMALE; FIBRINOGEN; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME;

EID: 54349114431     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12948     Document Type: Article

References (30)

1. Clavell L, Gelber R, Cohen H, Hitchcock-Bryan S, Cassady J, Tarbell N, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-63.
2. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-9.
3. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660-5.
4. Nagura E, Kimura K, Yamada K, Ota K, Maekawa T, Takaku F, et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1994;33:359-65.
5. Mitchell LG, Halton JM, Vegh PA, Barr RD, Venneri T, Pai KM, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol 1994;16:120-6.
6. Hunault M, Harousseau J, Delain M, Truchan-Graczyk M, Cahn J, Witz F, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone-marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028-37.
7. Hunault M, Truchan-Graczyk M, Caillot D, Harousseau JL, Bologna S, Himberlin C, et al. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. Haematologica 2007;92:1623-30.
8. Hoelzer D, Thiel E, Loffler H, Bodenstein H, Plaumann L, Buchner T, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984;64:38-47.
9. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
10. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 1994;5 (Suppl 1):S24-36.
11. Legnani C, Palareti G, Pession A, Poggi M, Vecchi V, Bianchini B, et al. Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children. Haemostasis 1988;18:179-86.
12. Miniero R, Pastore G, Saracco P, Messina M, Lange MM, Fiandino G, et al. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Am J Pediatr Hematol Oncol 1986;8:116-20.
13. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost 1995;21:390-401.
14. Leone G, Gugliotta L, Mazzucconi MG, De Stefano V, Belmonte MM, Dragoni F, et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study. Thromb Haemost 1993;69:12-5.
15. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, et al. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma 1996;21:85-92.
16. Hongo T, Okada S, Ohzeki T, Ohta H, Nishimura S, Hamamoto K, et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 2002;44:293-9.
17. Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol 1992;49:63-6.
18. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007;5:621-3.
19. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108:2216-22.
20. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol 2004;77:331-5.
21. Elliott M, Wolf R, Hook C, Pruthi R, Heit J, Letendre L, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004;45:1545-9.
22. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000;83:840-3.
23. Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595-9.
24. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97:508-16.
25. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 1994;83:386-91.
26. Sutor AH, Mall V, Thomas KB. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Padiatr 1999;211:201-4.
27. Gugliotta L, D'Angelo A, Mattioli Belmonte M, Vigano-D'Angelo S, Colombo G, Catani L, et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol 1990;74:465-70.
28. Mattioli Belmonte M, Gugliotta L, Delvos U, Catani L, Vianelli N, Cascione ML, et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. Haematologica 1991;76:209-14.
29. Mazzucconi MG, Gugliotta L, Leone G, Dragoni F, Belmonte MM, De Stefano V, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Blood Coagul Fibrinolysis 1994;5:23-8.
30. Pogliani EM, Parma M, Baragetti I, Mostarda G, Rivolta F, Maffe P, et al. L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy. Acta Haematol 1995;93:5-8.